Randomized trial demonstrates improved survival with morning immunotherapy in lung cancer, suggesting a link to circadian biology.
Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non–small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: